Table 6.
Results of Certainty of Quality.
| Author | Outcomes | Limitations | Inconsistency | Indirectness | Imprecision | Publication bias | Quality |
|---|---|---|---|---|---|---|---|
| Tan et al 32 | Objective response rate (ORR) | −1 A | 0 | 0 | 0 | 0 | Moderate |
| Disease control rate (DCR) | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of myelosuppression | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of leucopenia | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of anemia | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of thrombocytopenia | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of gastrointestinal reaction | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of diarrhea | −1 A | 0 | 0 | −1 C | 0 | LOW | |
| Incidence of nausea and vomiting | −1 A | −1 B | 0 | 0 | 0 | Low | |
| Incidence of hepatorenal toxicity | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of hepatotoxicity | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of renal toxicity | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of neurotoxicity | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Zhang et al 33 | Objective response rate (ORR) | −1 A | 0 | 0 | 0 | −1 D | Low |
| Disease control rate (DCR) | −1 A | 0 | 0 | 0 | −1 D | Low | |
| Overall Survival Time | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Improvement rate of KPS | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of leucopenia | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of nausea and vomiting | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of hand-foot syndrome | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Pain relief rate (PRR) | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of anemia | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of diarrhea | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of neurotoxicity | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of oral mucositis | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Sun et al 34 | Objective response rate (ORR) | −1 A | 0 | 0 | 0 | 0 | Moderate |
| Disease control rate (DCR) | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Overall survival time | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Score of KPS | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Quality of life improved rate (QIR) | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Pain relief rate (PRR) | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of nausea and vomiting | −1 A | −1 B | 0 | 0 | 0 | Low | |
| Incidence of diarrhea | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of leucopenia | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of thrombocytopenia | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of hepatotoxicity | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of renal toxicity | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of oral mucositis | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of alopecia | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of hand-foot syndrome | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of anemia | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of gastrointestinal reaction | −1 A | −1 B | 0 | 0 | 0 | Low | |
| Incidence of neurotoxicity | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Incidence of neutropenia | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of myelosuppression | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Zhang et al 35 | Disease control rate (DCR) | −1 A | 0 | 0 | 0 | 0 | Moderate |
| 1-year survival rate | −1 A | 0 | 0 | −1 C | 0 | Low | |
| 3-year survival rate | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of nausea and vomiting | −1 A | 0 | 0 | 0 | 0 | Moderate | |
| Chen et al 36 | Disease control rate (DCR) | 0 | 0 | 0 | 0 | 0 | High |
| Improvement rate of KPS | 0 | 0 | 0 | 0 | −1 D | Moderate | |
| Incidence of leucopenia | 0 | 0 | 0 | 0 | −1 D | Moderate | |
| Incidence of thrombocytopenia | 0 | 0 | 0 | 0 | −1 D | Moderate | |
| Incidence of anemia | 0 | −1 B | 0 | 0 | −1 D | Low | |
| Incidence of gastrointestinal reaction | 0 | −1 B | 0 | 0 | −1 D | Low | |
| Incidence of neurotoxicity | 0 | 0 | 0 | −1 C | −1 D | Low | |
| Incidence of hand-foot syndrome | 0 | 0 | 0 | −1 C | −1 D | Low | |
| Incidence of myelosuppression | 0 | 0 | 0 | −1 C | −1 D | Low | |
| Li et al 37 | Objective response rate (ORR) | −1 A | 0 | 0 | 0 | −1 D | Low |
| Improvement rate of KPS | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of neutropenia | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of leucopenia | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of anemia | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of thrombocytopenia | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of nausea and vomiting | −1 A | −1 B | 0 | −1 C | 0 | Very low | |
| Incidence of hepatotoxicity | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Incidence of neurotoxicity | −1 A | 0 | 0 | −1 C | 0 | Low | |
| Qiao et al 38 | Disease control rate (DCR) | 0 | 0 | 0 | 0 | −1 D | Moderate |
| Overall survival time | 0 | −1 B | 0 | 0 | −1 D | Low | |
| Incidence of nausea and vomiting | 0 | −1 B | 0 | 0 | −1 D | Low | |
| Incidence of leucopenia | 0 | 0 | 0 | 0 | −1 D | Moderate | |
| Liang et al 39 | Quality of life improved rate (QIR) | −1 A | −1 B | 0 | −1 C | 0 | Very low |
| Overall survival time | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Xu et al 40 | 1-year survival rate | −1 A | 0 | 0 | 0 | −1 D | Low |
| 3-year survival rate | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of leucopenia | −1 A | 0 | 0 | 0 | −1 D | Low | |
| Incidence of nausea and vomiting | −1 A | 0 | 0 | 0 | −1 D | Low | |
| Chen et al 41 | Objective response rate (ORR) | −1 A | 0 | 0 | 0 | 0 | Moderate |
| Improvement rate of KPS | −1 A | −1 B | 0 | 0 | −1 D | Very low | |
| Incidence of nausea and vomiting | −1 A | −1 B | 0 | 0 | −1 D | Very low | |
| Wang et al 42 | Score of KPS | −1 A | −1 B | 0 | 0 | −1 D | Very low |
| Incidence of leucopenia | −1 A | −1 B | 0 | −1 C | −1 D | Very low | |
| Incidence of anemia | −1 A | −1 B | 0 | −1 C | −1 D | Very low | |
| Incidence of thrombocytopenia | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of hepatotoxicity | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of renal toxicity | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of nausea and vomiting | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of diarrhea | −1 A | −1 B | 0 | −1 C | −1 D | Very low | |
| Incidence of neurotoxicity | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Wu et al 43 | Disease control rate (DCR) | −1 A | 0 | 0 | 0 | −1 D | Low |
| Improvement rate of KPS | −1 A | 0 | 0 | 0 | −1 D | Low | |
| Incidence of nausea and vomiting | −1 A | 0 | 0 | 0 | −1 D | Low | |
| Incidence of diarrhea | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Incidence of leucopenia | −1 A | −1 B | 0 | 0 | −1 D | Very low | |
| Incidence of neurotoxicity | −1 A | 0 | 0 | −1 C | −1 D | Very low | |
| Zhao et al 44 | Disease control rate (DCR) | 0 | −1 B | 0 | 0 | −1 D | Low |
| Incidence of adverse reactions (Mainly including gastrointestinal reaction and myelosuppression) | 0 | 0 | 0 | −1 C | −1 D | Low |
A, The included studies have a large bias in methodology such as randomization, allocation concealment, and blinding. B, The confidence interval overlaps less or the I2 value of the combined results was larger. C, The sample size from the included studies does not meet the optimal sample size or the 95% confidence interval crosses the invalid line. D, The funnel chart is asymmetry.